Phosphonomethyl phenylalanine (Pmp) is a non-hydrolyzable phosphotyrosyl (pTyr) mimetic, which has been incorporated into eleven-mer Pmp-containing peptides that have previously been reported to competitively inhibit the protein-tyrosine phosphatases PTP1 and PTP 1B. We have recently shown that phosphonodifluoromethyl phenylalanine (F(2)Pmp) is superior to Pmp as a pTyr mimetic in SH2 domain-binding peptides. Herein we find using the hexameric peptide sequence Ac-D-A-D-E-X-L-amide, where X = (D/L)-Pmp or L-F(2)Pmp, that the half maximal inhibition values of these two peptides against PTP 1B-mediated dephosphorylation of autophosphorylated insulin receptor to be 200 mu M and 100 nM, respectively. These data indicate that F(2)Pmp induces a three orders of magnitude enhancement in affinity relative to Pmp, resulting in an exceptionally potent peptide-based PTP inhibitor. We conclude that F(2)Pmp may be a generally useful tool in the preparation of selective, high affinity PTP inhibitors. (C) 1994 Academic Inc.
机构:Cancer Research Campaign Beatson Laboratories, CRC Department of Medical Oncology, University of Glasgow, Glasgow, G61 1BD, Garscube Estate, Switchback Road, Bearsden
BRUNTON, VG
WORKMAN, P
论文数: 0引用数: 0
h-index: 0
机构:Cancer Research Campaign Beatson Laboratories, CRC Department of Medical Oncology, University of Glasgow, Glasgow, G61 1BD, Garscube Estate, Switchback Road, Bearsden
机构:Laboratory of Medicinal Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Bldg. 37
BURKE, TR
SMYTH, MS
论文数: 0引用数: 0
h-index: 0
机构:Laboratory of Medicinal Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Bldg. 37
SMYTH, MS
NOMIZU, M
论文数: 0引用数: 0
h-index: 0
机构:Laboratory of Medicinal Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Bldg. 37
NOMIZU, M
OTAKA, A
论文数: 0引用数: 0
h-index: 0
机构:Laboratory of Medicinal Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Bldg. 37
OTAKA, A
ROLLER, PP
论文数: 0引用数: 0
h-index: 0
机构:Laboratory of Medicinal Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Bldg. 37
机构:Cancer Research Campaign Beatson Laboratories, CRC Department of Medical Oncology, University of Glasgow, Glasgow, G61 1BD, Garscube Estate, Switchback Road, Bearsden
BRUNTON, VG
WORKMAN, P
论文数: 0引用数: 0
h-index: 0
机构:Cancer Research Campaign Beatson Laboratories, CRC Department of Medical Oncology, University of Glasgow, Glasgow, G61 1BD, Garscube Estate, Switchback Road, Bearsden
机构:Laboratory of Medicinal Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Bldg. 37
BURKE, TR
SMYTH, MS
论文数: 0引用数: 0
h-index: 0
机构:Laboratory of Medicinal Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Bldg. 37
SMYTH, MS
NOMIZU, M
论文数: 0引用数: 0
h-index: 0
机构:Laboratory of Medicinal Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Bldg. 37
NOMIZU, M
OTAKA, A
论文数: 0引用数: 0
h-index: 0
机构:Laboratory of Medicinal Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Bldg. 37
OTAKA, A
ROLLER, PP
论文数: 0引用数: 0
h-index: 0
机构:Laboratory of Medicinal Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Bldg. 37